Ribo Unlocks New siRNA Frontiers Beyond the Liver with RiboPepSTAR™

SUZHOU, China – March 20, 2026 – Suzhou Ribo Life Science Co., Ltd. has unveiled a significant advancement in RNA interference (RNAi) technology that promises to extend the reach of powerful gene-silencing therapies far beyond their traditional focus on the liver. At the prestigious RNA Leaders Europe Conference in Vienna, the company presented its proprietary RiboPepSTAR™ platform, a novel system designed for precise delivery of small interfering RNA (siRNA) to a range of vital organs, including the kidney, heart, and adipose tissue.

The announcement signals a pivotal moment for siRNA therapeutics, a class of medicines that works by silencing specific genes responsible for disease. While highly effective, the utility of first-generation siRNA drugs has been largely confined to liver-related conditions due to the natural uptake of their delivery vehicles by that organ. Ribo’s new platform aims to shatter this limitation, potentially unlocking new treatments for a host of complex renal, cardiac, and metabolic diseases.

This development builds on the company's established success with RiboGalSTAR™, a liver-targeting platform that has already underpinned seven clinical programs and global partnerships valued at over USD 6 billion. With RiboPepSTAR™, the company is now strategically expanding its focus to some of medicine's most challenging and underserved areas.

Precision Targeting for Untreated Diseases

The core innovation of RiboPepSTAR™ lies in its ability to conjugate siRNA molecules with specific peptides that act as homing signals, guiding the therapeutic payload directly to target cells in other organs. The preclinical data presented by Ribo offers a compelling glimpse into the platform's potential.

For kidney diseases, a notoriously difficult area for drug development, RiboPepSTAR™ demonstrated selective uptake in the proximal tubular cells—a key site for many renal pathologies. In studies spanning from rodents to non-human primates (NHPs), the platform achieved up to 80% knockdown of the target gene. Crucially, this was validated in a type 2 diabetes disease model, where researchers observed a robust reduction in kidney-specific biomarkers, providing physiological proof of concept.

In cardiac applications, a conjugate designed to target the heart showed sustained gene knockdown in a mouse model. The effect was highly specific, with minimal activity detected in muscle tissue and negligible impact on the liver and kidneys, underscoring the platform’s precision.

The most dramatic results came from studies targeting adipose (fat) tissue. In NHPs, systemic administration of a RiboPepSTAR™ conjugate resulted in a staggering 96% gene knockdown, demonstrating potent and selective engagement with metabolic tissues. This high level of efficacy opens the door to new therapeutic strategies for obesity and other metabolic disorders.

In parallel, Ribo is developing a multi-target siRNA platform that allows a single molecule to silence two or more genes simultaneously. This approach could offer synergistic benefits for complex diseases driven by multiple genetic pathways, potentially delivering enhanced therapeutic effects with a single drug.

Navigating the Path to Human Trials

Beyond promising preclinical data, Ribo has already taken a concrete step toward clinical application. The company announced that its first kidney-targeted drug, developed using the RiboPepSTAR™ platform, has officially entered the Investigational New Drug (IND)-enabling phase. This is a critical regulatory milestone that involves a battery of preclinical studies to assess a drug candidate's safety, toxicity, and manufacturing viability before it can be tested in humans.

Successfully navigating the IND-enabling stage and gaining approval from regulatory bodies like the FDA or EMA to begin Phase 1 clinical trials is a resource-intensive process that can take months or even years. However, reaching this stage signifies that the initial data is strong enough to warrant advancement, moving the therapy one step closer to potentially helping patients with chronic kidney disease.

Racing for Dominance in a Competitive Field

Ribo's push into extrahepatic delivery places it at the forefront of a highly competitive and rapidly advancing field. The challenge of targeting organs beyond the liver is a key focus for the entire RNAi industry, with numerous biopharmaceutical companies, from established giants to nimble startups, racing to develop their own solutions.

In the renal space, companies like Rona Therapeutics and Rigerna Bio are also advancing kidney-targeting siRNA platforms, with both reporting promising NHP data and IND-enabling progress. The cardiovascular sector is similarly active, marked by major collaborations such as the multi-billion dollar partnership between Novartis and Argo Biopharmaceuticals. Meanwhile, the vast market for metabolic diseases has attracted heavyweights like Eli Lilly and Boehringer Ingelheim, who are investing billions into RNAi-based approaches for conditions like obesity and metabolic dysfunction-associated steatohepatitis (MASH).

This intense competition underscores the immense perceived value of unlocking extrahepatic tissues. A successful platform that can safely and effectively deliver siRNA to the heart, kidneys, or central nervous system would represent a paradigm shift in modern medicine, with enormous clinical and commercial implications.

Strategic Growth on a Solid Foundation

Ribo's ambitious expansion is backed by a solid strategic and financial foundation. The company made a successful debut on the Hong Kong Stock Exchange (HKEX: 6938) in January 2026, raising over USD 200 million in an initial public offering that was heavily oversubscribed, signaling strong investor confidence. The proceeds are earmarked for advancing its clinical pipeline, upgrading its technology platforms, and funding further R&D.

This financial strength is built upon the proven success of its RiboGalSTAR™ platform and a history of securing high-value partnerships, such as a recent exclusive licensing agreement with Madrigal for a MASH therapeutic. With R&D centers in China and Sweden, Ribo has established a global footprint to support its end-to-end drug development process.

By leveraging its deep expertise in siRNA chemistry and its established track record, Ribo is positioning itself not just as a participant but as a leader in the next wave of RNAi innovation. The development of RiboPepSTAR™ and the multi-target platform represents a calculated strategic leap, transforming the company from a liver-focused specialist into a diversified powerhouse with the potential to address a much broader spectrum of human diseases.